GenEdit and Editas announce a worldwide, exclusive license and collaboration to enable safer and more effective delivery of CRISPR-based therapeutics.
In the superheated market for batteries, promising lab developments often get overhyped by startups. ‘Liar, liar, battery supplier.’
